Skip to search boxSkip to navigationSkip to main content

Catheterized guinea pigs infected with Ebola Zaire virus allows safer sequential sampling to determine the pharmacokinetic profile of a phosphatidylserine-targeting monoclonal antibody

*Corresponding author for this work
Research Output:
Contribution to journal
Article
Research
Peer-review

Abstract

Sequential sampling from animals challenged with highly pathogenic organisms, such as haemorrhagic fever viruses, is required for many pharmaceutical studies. Using the guinea pig model of Ebola virus infection, a catheterized system was used which had the benefits of allowing repeated sampling of the same cohort of animals, and also a reduction in the use of sharps at high biological containment. Levels of a PS-targeting antibody (Bavituximab) were measured in Ebola-infected animals and uninfected controls. Data showed that the pharmacokinetics were similar in both groups, therefore Ebola virus infection did not have an observable effect on the half-life of the antibody.

Research Output Information

Output type

Research Output:
Contribution to journal
Article
Research
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 108-111 (4 pages)

Journal (Volume, Issue Number)

Antiviral Research (Volume 97, Issue 2)

Publication milestones

  • Published - 02/2013

Publication status

Published - 02/2013

ISSN

0166-3542

Publication IDs

  • Scopus: 84871894016
  • PubMed: 23165089

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well